India, April 17 -- Prothea Technologies, a new spin-out company from the Universities of Bath and Edinburgh, has launched with a mission to enable lung cancer biopsy and treatment in a single visit.

The firm has attracted €12M (£10.3M) of investment as it seeks to develop a medical device to quickly diagnose lung cancer lesions using a combined endoscope and image-processing system capable of examining the molecular structure of lung lesions. The team also wants to develop a laser-ablation catheter to treat lesions immediately after diagnosis, reducing time-to-treatment from weeks to minutes, relieving hospital pressures and improving patient outcomes.

Prothea Technologies combines extensive optical-fibre research expertise a...